Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer

Farjana Afrin 1,2,†, Mengna Chi 1,2,†, Andrew L. Eamens 3, Ryan J. Duchatel 1,2,+, Alicia M. Douglas 1,2, Jennifer Schneider 2,4, Craig Gedye 1,2,5, Ameha S. Woldu 1,2,*, and Matthew D. Dun 1,2,*

1 Cancer Signalling Research Group, Medical Biochemistry, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia; Farjana.Afrin@uon.edu.au (F.A.); Mengna.Chi@newcastle.edu.au (M.C.); Ryan.Duchatel@newcastle.edu.au (R.J.D.); Alicia.Douglas@newcastle.edu.au (A.M.D.); Craig.Gedye@newcastle.edu.au (C.G.)
2 Priority Research Centre for Cancer Research, Innovation & Translation, Faculty of Health and Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia; Jennifer.Schneider@newcastle.edu.au
3 Centre for Plant Science, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia; Andy.Eamens@newcastle.edu.au
4 Priority Research Centre for Chemical Biology and Clinical Pharmacology, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW 2308, Australia
5 Calvary Mater Newcastle, Waratah, NSW 2298, Australia
* Correspondence: Ameha.Woldu@newcastle.edu.au (A.S.W.); Matt.Dun@newcastle.edu.au (M.D.D.); Tel.: +61-02-4921-7807 (A.S.W.); +61-02-4921-5693 (M.D.D.)
† These authors contributed equally to this work.

Received: 7 April 2020; Accepted: 20 April 2020; Published: 23 April 2020

Abstract: Cannabis has been used to relieve the symptoms of disease for thousands of years. However, social and political biases have limited effective interrogation of the potential benefits of cannabis and polarised public opinion. Further, the medicinal and clinical utility of cannabis is limited by the psychotropic side effects of Δ9-tetrahydrocannabinol (Δ9-THC). Evidence is emerging for the therapeutic benefits of cannabis in the treatment of neurological and neurodegenerative diseases, with potential efficacy as an analgesic and antiemetic for the management of cancer-related pain and treatment-related nausea and vomiting, respectively. An increasing number of preclinical studies have established that Δ9-THC can inhibit the growth and proliferation of cancerous cells through the modulation of cannabinoid receptors (CB1R and CB2R), but clinical confirmation remains lacking. In parallel, the anti-cancer properties of non-THC cannabinoids, such as cannabidiol (CBD), are linked to the modulation of non-CB1R/CB2R G-protein-coupled receptors, neurotransmitter receptors, and ligand-regulated transcription factors, which together modulate oncogenic signalling and redox homeostasis. Additional evidence has also demonstrated the anti-inflammatory properties of cannabinoids, and this may prove relevant in the context of peritumoural oedema and the tumour immune microenvironment. This review aims to document the emerging mechanisms of anti-cancer actions of non-THC cannabinoids.

Keywords: cannabinoids; cannabidiol; Δ9-tetrahydrocannabinol; cannabinoid receptors; G-protein-coupled receptors; cancer; apoptosis; inflammation

1. Introduction

The flowering herb Cannabis sativa L. (Cannabaceae) has been used in traditional Eastern medicines as an analgesic, anxiolytic, anticonvulsant, sedative, and hypnotic, for almost 5000 years [1]. More
recently, medicinal cannabis has been studied for its efficacy in the treatment of epilepsy, inflammation, anxiety, nausea and cancer-related pain [1]. Emerging anecdotal and preclinical evidence has further demonstrated that cannabis can also modulate tumour growth [2]: a finding that has renewed interest in the use of cannabis as a potential anti-cancer therapeutic [3], in spite of the limited available clinical trial data. Encouragingly, the recent rapid change to the legislative status of recreational and medicinal cannabis is now enabling appropriate assessment of the use of cannabis and cannabinoids in the clinical setting [4].

The two main cannabinoids in cannabis are Δ⁹-tetrahydrocannabinol (Δ⁹-THC) and cannabidiol (CBD). Each of these cannabinoids demonstrate very different pharmacological actions. Concerns about the undesirable effects caused by the primary psychotropic constituent, Δ⁹-THC, have led to hesitancy to prescribe cannabis for medicinal use. Tachycardia, anxiety, altered cognitive perception, as well as other behavioural issues, are commonly reported symptoms stemming from the use of Δ⁹-THC [5,6]. Further, Δ⁹-THC can also alter immune system function, and increase the susceptibility of a patient to microbial infections [7,8]. In spite of the demonstrated anti-cancer properties of Δ⁹-THC, this cannabinoid has also been revealed to promote tumour growth, invasion and metastasis in some cancer cell types. In breast cancer for example, Δ⁹-THC-mediated increased tumour growth and metastasis was associated with inhibition of the anti-tumour specific immune responses in vivo [8]. A retrospective analysis further demonstrated that cannabis use is associated with the markedly reduced effectiveness of immune checkpoint inhibitors [9]. Therefore, rigorous and meticulous anti-cancer research, both pre-clinically and clinically, is required to provide the necessary medical rationale to support the use of medicinal cannabis as a complementary, or alternative, anti-cancer treatment option.

Conversely, the undesirable side effects, such as drug dependence/tolerance/abuse issues shrouding the use of Δ⁹-THC is not seen with CBD (the second most abundant cannabinoid in cannabis). Indeed, CBD is well-tolerated in patients, even at relatively high doses in contrast with Δ⁹-THC, which has a maximum tolerated daily dose of only 15 to 90 mg in adult patients, and this daily maximum requires ongoing, individualised adjustment, to ensure that side effects are managed for each patient [10]. Furthermore, CBD has anti-psychotic, anti-convulsive, anxiolytic, sedative and anti-inflammatory properties, none of which have been reported for Δ⁹-THC [11]. The more recently reported positive health benefits of CBD, and for other non-THC cannabinoids, has promoted and accelerated research into non-THC cannabinoids [11–13]. In spite of these promising findings, legislation continues to lag. For example, the concentration of Δ⁹-THC required by law to classify cannabis as being a ‘low-THC’ variety, varies from country to country. Presently, in the United States, cannabis is permitted for therapeutic use in 24 states and territories, including the District of Columbia, Guam, Puerto Rico and the U.S. Virgin Islands, with an additional 16 states allowing the use of low Δ⁹-THC/high CBD products (commonly referred to as ‘hemp’) for medical reasons, albeit in limited situations [14]. In most Australian states and territories, the limit of Δ⁹-THC in hemp must be below 1% of total plant material [15,16]. This is in direct contrast with the legislation of the U.S. For example, the state law of New Jersey stipulates that a substance with a Δ⁹-THC content of less than 10% (by weight) classifies the substance as low-THC [17]. This highlights the significant variation in global cannabis classification systems, and as such, creates considerable complexity when attempting to reveal the clinical efficacy of low-THC cannabis and non-THC cannabinoids.

Effects of Cannabis on Human Health

Medicinal cannabis is increasingly being used in the clinical setting [18–21]. However, contrasting views on the long- and short-term impacts on patient health, following the sustained use of Δ⁹-THC cannabis, persist. There is no doubt that recreational use is associated with substantial adverse health effects. Still, the burden of disease stemming from the recreational use of cannabis is much lower than other commonly used legal and illicit substances [22]. Reports of brain damage and cognitive dysfunction [23] are contrasted by clinical studies that show improved cognitive function with the controlled use of Δ⁹-THC cannabis [24]. Furthermore, Δ⁹-THC and synthetic cannabinoids
(sCB) (discussed in Section 2), protected normal rat astrocytes from induced cell death post exposure to ceramide (N-acetylsphingosine cell-permeable analogue; see Section 3.4.1), via the activation of phosphatidylinositol 3-kinases –PI3K/protein kinase B–Akt/p90 ribosomal S6 kinase–RSK, survival signalling pathways [25]. Conversely, Lenzi et al. showed that sCBs have mutagenic capabilities in healthy human lymphoblasts and can cause chromosomal damage at the concentration range of 25 to 50 µM [26]. Koller et al. also demonstrated that sCBs can cause DNA damage in human lymphocytes [27].

There is unanimous support to encourage harm minimisation approaches in order to decrease medicinal or recreational cannabis use while pregnant or postpartum [28]. For example, Δ⁹-THC containing cannabis use is negatively correlated with foetal birth weight (up to a 450 g reduction) [29], and the development of neurotransmission systems, with the endocannabinoid system playing a number of important roles in brain development. Although the evidences so far are ambiguous, it is unsurprising that prenatal exposure to cannabis may have neurocognitive consequences, including affective mental disorders (anxiety and depression), and attention deficit hyperactivity disorders (reviewed in [30]), which are also common occurrences in the adult life of long-term Δ⁹-THC cannabis users (reviewed in [31]). Interestingly, CBD elicits different neurocognitive activity compared with that of Δ⁹-THC [32]. In some cases however, CBD can induce somnolence and fatigue [33], akin to the use of Δ⁹-THC. CBD also has the ability to cross the placenta and to reach breast-milk, further highlighting the need to abstain while pregnant or when postpartum [33]. Due to the risk of accumulation, CBD dose adjustment is required in patients with hepatic impairment [34]. CBD may cause hepatotoxicity, as mouse modelling showed that an acute dose of 2460 mg/kg (24 hr), or a sub-acute dose of 615 mg/kg (10 days), increased markers of liver damage, including liver-to-body weight ratios, plasma alanine aminotransferase and aspartate aminotransferase enzyme levels, and total bilirubin after 3–4 days of treatment [35]. Furthermore, there is currently limited evidence regarding the long-term safety and cognitive consequences of the sustained consumption of CBD, either in the recreational or medicinal setting [36].

2. Cannabinoids

To date, over 620 chemical compounds, including cannabinoids, cannabis-specific prenylated flavones (cannflavin A and B), and terpenoids, have been isolated from traditional cannabis [37]. Unlike recreational varieties of the cannabis plant that contain high levels of Δ⁹-tetrahydrocannabinolic acid (the biosynthetic precursor of Δ⁹-THC), the primary cannabinoids in low-THC cannabis/hemp include cannabidiolic acid (CBDA), cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), and their decarboxylated forms cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC), respectively [37,38].

Cannabinoids (a group of terpenophenolics) are highly abundant in this plant species, with more than 100 different cannabinoids identified as constituents of the cannabis plant [37]. Endogenous and exogenous cannabinoids can be separated into three main groups, including; (1) endocannabinoids (eCBs); (2) phytocannabinoids (pCBs), and; (3) sCBs [39]. The eCBs are an endogenous group of lipid-based, retrograde neurotransmitters that bind to cannabinoid receptors (CBRs) and related receptor proteins in animals [40]. There are two major human eCBs, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) [41]. Both AEA and 2-AG are derived from the non-oxidative metabolism of membrane phospholipids [42], with AEA degraded by the fatty acid amide hydrolase (FAAH) [40], whereas the monoarachidonylglycerol lipase (MAGL) enzyme is primarily responsible for terminal 2-AG degradation [43]. pCBs (or simply cannabinoids) are naturally occurring plant-derived cannabinoids unique to the cannabis plant, with the two major chemicals derived from the common precursor, cannabigerol (CBG) [44]. sCBs, such as WIN-55, 212-2, HU120, JWH-015 and JWH-133, are classified on the basis of their chemical structure and affinity for CBRs [39].
3. Role of Cannabinoids in Cancer

In vitro and in vivo animal models have shown that cannabinoids have selective anti-cancer activity in a wide range of cancer cell lines, including breast [13], prostate [45], cervical [46], brain [47,48], colon [49] and leukaemia/lymphoma [50,51] (Table 1). A variety of cannabinoids, and cannabinoid extracts, have been subjected to several phase I/II clinical trials (summarised in Table 2). The mechanisms of anti-cancer action for both $\Delta^9$-THC and non-THC cannabinoids remains enigmatic, however, most studies suggest that $\Delta^9$-THC induces apoptosis and cytotoxicity via CBR-dependent pathways [50–52], while non-THC cannabinoids, such as CBD, modulate the activity of other de-orphan and orphan G-protein-coupled receptors (GPCRs) and non-GPCRs.
| Cancer Type  | Model/Cell Line       | Compound                  | Effective Dose               | Effects                                                                 | References |
|-------------|-----------------------|---------------------------|----------------------------|------------------------------------------------------------------------|------------|
| Breast      | MCF-7                 | Cannabidiol (CBD)         | 8.2 µM/2.6 mg/L             | Inhibition of cancer cell growth and proliferation                     | [13]       |
|             |                       | CBD-rich extract (~70%   | 6.0 µM/2.7 mg/L             |                                                                         |            |
|             |                       | CBD)                     |                            |                                                                         |            |
|             |                       | Δ⁹-tetrahydrocannabinol   | 14.2 µM/4.5 mg/L           |                                                                         |            |
|             |                       | (Δ⁹-THC)                 |                            |                                                                         |            |
|             |                       | AEA                      | 1.4 µM/0.5 mg/L            |                                                                         | [53]       |
|             | MDA-MB-231            | CBD                      | 2.2 µM/0.7 mg/L            | Inhibition of cancer cell growth, induction of apoptosis                | [54]       |
|             |                       | WIN-55,212-2, JWH-133    | 10 µM/4.3 mg/L, 5.0 µM/3.1 mg/L | Inhibition of proliferation                                           | [55]       |
|             | Xenograft-MBA-MD-231 cells | CBD                  | 5 mg/kg (i.p.)           | Reduced tumour size and volume                                         | [13]       |
|             |                       | CBD-rich extract (~70%   | 6.5 mg/kg (i.p.)           |                                                                         |            |
|             |                       | CBD)                     |                            |                                                                         |            |
|             |                       | WIN-55,212-2, JWH-133    | 5 mg/kg (i.p.)            | Reduced tumour growth, angiogenesis and metastasis                     | [55]       |
| Cervical    | SiHa                  | CBD                      | 3.2 µg/mL/1.5 mg/L         | Inhibition of cancer cell growth, induction of apoptosis                | [46]       |
|             | HeLa                  | CBD                      | 3.2 µg/mL/1.5 mg/L         |                                                                         |            |
|             | ME-180                |                          | 1.5 µg/mL/1.5 mg/L         |                                                                         |            |
| Colon       | HCT8                  | CB-13                     | >50 nmol/L/0.02 mg/L       | Inhibition of cancer cell growth                                       | [49]       |
|             | SW480                 | CBG                      | ≥3.0 µM/0.9 mg/L           | Reduced viability of cancer cells                                      | [56]       |
|             | HCA7                  | CBG                      | 3 and 10 mg/kg (i.p.)      | Inhibition of tumour growth                                            |            |
|             | HCT15                 | CBG                      |                              |                                                                         |            |
|             | HCT-116               | CBG                      |                              |                                                                         |            |
|             | Xenograft-HCT-116     | CBG                      |                              |                                                                         |            |
| Cancer Type      | Model/Cell Line | Compound       | Effective Dose          | Effects                                               | References |
|-----------------|-----------------|----------------|-------------------------|-------------------------------------------------------|------------|
| Glioma          | U251            | CBD            | 0.6 µM/0.2 mg/L         | Inhibition of cancer cell growth                       | [47]       |
|                 |                 | Δ⁹-THC         | 3.3 µM/1 mg/L           |                                                       |            |
|                 | U87             | CBD            | 0.6 µM/0.2 mg/L         |                                                       |            |
|                 |                 | Δ⁹-THC         | 3.3 µM/1 mg/L           |                                                       |            |
|                 | GSC3832         | CBD            | 3.5 µM/1.1 mg/L         | Inhibition of viability                                | [57]       |
|                 | GSC387          | CBD            | 2.6 µM/0.8 mg/L         |                                                       |            |
|                 | U87MG           | CBD            | >25 µM/>7.9 mg/L         | Reduced viability and induce cancer cell death        | [58]       |
|                 | Xenograft-U87   | CBD            | 6.7 mg with 75 mg micro-particles | Inhibition of tumour growth                           | [59]       |
| Multiple        | U266            | CBD            | 32.2 µM/10.1 mg/L       | Reduced cancer cell viability, increased cytotoxicity, inhibition of cancer cell migration | [60,61]   |
| Myeloma         | U266TRPV2       | CBD            | 19.8 µM/6.2 mg/L        |                                                       |            |
|                 | RPMI            | CBD            | 22.4 µM/7.0 mg/L        |                                                       |            |
|                 |                 | Δ⁹-THC         | 30.8 µM/9.7 mg/L        |                                                       |            |
|                 | RPMI TRPV2      | CBD            | 13.5 µM/4.2 mg/L        |                                                       |            |
Table 2. Clinical trials using cannabinoids for the treatment of cancer *.

| Trial No.               | Cancer Type/s                      | Study Type/Phase                   | Treatments                                                                 | Dose of Cannabinoids or Cannabis Products | Delivery  | Outcome # |
|-------------------------|-----------------------------------|------------------------------------|----------------------------------------------------------------------------|--------------------------------------------|-----------|-----------|
| NCT01812603; NCT01812616 | Glioblastoma multiforme (GBM)     | Interventional (Clinical Trial)/Phase 1 & Phase 2 | Combination of Temozolomide (TMZ) and Sativex (1:1 Δ9-THC:CBD) | Dose-intense TMZ with a maximum of 32.4 mg THC and 30 mg CBD per day | Oral spray | Increased 39% of 1-year survival rate |
| NCT02255292             | Solid tumour                      | Interventional (Clinical Trial)/Phase 2 | CBD                                                                          | Unknown                                    | Unknown    | Not yet recruiting |
| NCT01489826             | Solid tumour                      | Interventional (Clinical Trial)/Phase 1 | Dexanabinol (HU-211; a synthetic cannabinoid)                              | 2–36 mg/kg once weekly–3 doses in 21-day cycle | Intravenous infusion | Progression-free survival increased |
| NCT01654497             | Brain cancer                      | Interventional (Clinical Trial)/Phase 1 | Dexanabinol (HU-211)                                                        | 2–44 mg/kg once weekly–4 doses in 28-day cycle | Intravenous infusion | No relevant results available |
| NCT03431363             | Head and neck cancer              | Observational                      | Medically certified cannabis with adjuvant chemoradiation                   | Dosing options to be stratified into 3 groups viz. standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced | Smoke     | Recruiting |
| NCT01654497             | Hepatocellular carcinoma; pancreatic cancer | Interventional (Clinical Trial)/Phase 1 | Dexanabinol (HU-211) monotherapy and in combination with chemotherapy | MTD ** once a week                           | Intravenous infusion | Ongoing |
| NCT03245658             | Pancreatic cancer                 | Interventional (Clinical Trial)/Phase 2 | 1:2 Δ9-THC:CBD                                                              | Individually titrated doses on daily basis; for 4 weeks | Oral drops | Not yet recruiting |
| NCT03529448             | GBM                               | Interventional (Clinical Trial)/Phase 1 & Phase 2 | TN-TC11G (1:1 Δ9-THC:CBD) combination with temozolomide and radiotherapy | Total daily dose of 10–160 mg, after meal | Unknown    | Not yet recruiting |
| NCT03617692             | Non-small-cell lung carcinoma (NSCLC) metastasis | Observational | Cannabis products | Products, dose and administration frequency decided by study participants | Oral administration | Recruiting |

*Note: Δ9-THC: Δ9-tetrahydrocannabinol, CBD: cannabidiol, TMZ: temozolomide, MTD: maximum tolerated dose, ECOG: Eastern Cooperative Oncology Group.

#Outcome: Increased 39% of 1-year survival rate, Not yet recruiting.
| Trial No. | Cancer Type/s | Study Type/Phase | Treatments | Dose of Cannabinoids or Cannabis Products | Delivery | Outcome \(^\lambda\) |
|-----------|----------------|------------------|------------|------------------------------------------|----------|-----------------|
| NCT03052738 | Paediatric CNS tumour | Observational | Medical marijuana-derived products | Method of delivery, strain used, dosing and frequency decided by study participants | Recruiting |
| NCT03687034 | Glioblastoma | Interventional (Clinical Trial)/Phase 1 | CBD with standard of care | Escalating doses of CBD | Oral sublingual formulation | Not yet recruiting |
| NCT03607643 | GI malignancies (pancreas, liver rectum, colon, or gall bladder), multiple myeloma, or GBM | Interventional (Clinical Trial)/Phase 1 & Phase 2 | CBD with standard of care chemotherapy | 100 mg twice daily before meal | Oral sublingual formulation | Not yet recruiting |
| ACTRN12617001287325 | GBM | Interventional (Clinical Trial)/Phase 2 | 1:1 \(\Delta^9\)-THC:CBD (6 mg/mL:6 mg/mL) or 1:4 CBD: \(\Delta^9\)-THC (3.8 mg/mL:15 mg/mL) and standard treatment *** | Starts at 0.25 mL at night and each night titrated up or downwards by 0.05 mL based on participant’s response | Oral oily liquids | No relevant results available |
| ACTRN12619000265178 | Any cancer | Interventional (Clinical Trial)/phase 4 | \(\Delta^9\)-THC or 1:1 \(\Delta^9\)-THC:CBD. Combined with standard treatment for advanced cancer and symptoms | Starts at 2.5 mg THC three times a day in cannabis naive patients, and 5 mg THC three times a day in previous users. Dosage adjusted based on patient’s response up to a maximum of 30 mg THC per day. | Oral oily liquids | Recruiting |
| ACTRN12619000037101 | Any cancer | Interventional (Clinical Trial)/Phase 2 | 1:1 \(\Delta^9\)-THC:CBD | Total daily dose of 2.5 mg:2.5 mg–30 mg:30 mg | Oral oily liquid | Recruiting |
| ACTRN12618001220257 | Any cancer | Interventional (Clinical Trial)/Phase 2 | CBD | Total daily dose of 50 mg–600 mg | Oral oily liquid | Recruiting |
Table 2. Cont.

| Trial No.       | Cancer Type/s | Study Type/Phase | Treatments                                      | Dose of Cannabinoids or Cannabis Products | Delivery            | Outcome ¹                             |
|-----------------|---------------|------------------|------------------------------------------------|-------------------------------------------|---------------------|-------------------------------------|
| ACTRN1261800    | Any cancer    | Interventional (Clinical Trial)/Phase 1 | CBD or Δ⁹-THC with palliative care | Total daily doses of 50 mg–600 mg/day for CBD or 2.5 mg–30 mg for THC | Oral oily liquid   | Doses of THC and CBD used in the study were generally well tolerated and up to 50% of the participants had an overall improvement in their condition since starting cannabis but results need to be replicated in placebo controlled trial [62] |
| 1205224         |               |                  |                                                |                                           |                     |                                     |
| ACTRN1261600    | Any cancer    | Interventional (Clinical Trial)/Phase 2 & Phase 3 | 1:1 Δ⁹-THC/CBD with chemotherapy | 2.5 mg THC and 2.5 mg CBD, once the day before chemotherapy and three times daily for 5 days for the first 5 days of participants' chemotherapy cycle and for three consecutive cycles. | Oral Capsule       | Recruiting                          |
| 1036404         |               |                  |                                                |                                           |                     |                                     |

* Sources: www.clinicaltrials.gov and www.anzctr.org.au (ANZCTR), ** Maximum Tolerated Dose, *** Includes chemotherapy, radiation, immunotherapy, or any other cancer related treatment requested by the participants medical specialists and including best supportive and palliative care, ¹ As at 3 April 2020.
3.1. Cannabinoid Receptors (CBRs)

Notably, ∆9-THC and sCBs elicit central and peripheral effects via stimulation of the cannabinoid GPCRs, CB1R (CNR1) and CB2R (CNR2) [63,64], whereas CBD shows negligible affinity for CB1R or CB2R [65]. CB1R and CB2R are expressed on both extracellular and intracellular membranes of organelles, such as the nucleus, mitochondria and Golgi apparatus [66]. CB1R is primarily found in the brain and in the peripheral central nervous system (CNS), whereas CB2R is predominantly expressed in immune cells [64]. Thus, the involvement of CB1R is more likely to drive psychotropic activity, with the weight of evidence showing that CB2R activation modulates immunological responses [67]. However, CB2R modulated neurological function and its expression in the CNS on microglia, astrocytes, and subpopulations of neurons has also been reported (reviewed in [68]). Nevertheless, both CB1R and CB2R are linked to the anti-cancer effects of ∆9-THC [69,70].

3.2. Non-THC Cannabinoids Are Ligands for Calcium Selective Ion Channels and Orphaned/De-Orphaned G-Protein-Coupled Receptors

Non-THC cannabinoids, such as CBD, show a reduced affinity for the classical CBRs, acting as an antagonist or inverse agonist of CBRs, with an inhibitory constant (Ki) of 1458.5 ± 158.5 nM for CB1R and 372.4 ± 57.5 nM for CB2R [71]. Therefore, it is unlikely that CB1R and CB2R play a significant role in the anti-cancer effects of CBD. Transient receptor potential vanilloid (TRPV) calcium selective ion channels are targets for cannabinoids [72,73] (discussed in Section 3.2.1). The majority of reports highlight a role for non-THC cannabinoids as ligands for de-orphaned GPCRs, such as G-protein-coupled receptor 55 (GPR55) (discussed in Section 3.2.2) and GPR119. However, GPR119 is only activated by eCBs analogues, including oleoylethanolamide and palmitoylethanolamide, rather than pCBs or sCBs. Therefore, GPR119 is not discussed in detail here, other than to outline that its agonism by specific ligands (such as MBX-2982 or GSK1292263), re-sensitises breast cancer cells that have developed resistance to gefitinib [74]. Uniquely, CBD is a ligand for the orphan GPCRs, GPR3, GPR6 and GPR12 (discussed in Section 3.2.3).

3.2.1. Transient Receptor Potential Channels of the Vanilloid Subtype–TRPV1/2

The transient receptor potential (TRP) superfamily of transmembrane ion channels TRPV1–TRPV4, and TRPA1 and TRPM8, are termed the ionotropic CBRs. The activation of TRPV1 by CBD, and of TRPV2 by CBD and ∆9-THC, inhibits human glioma cell proliferation and viability in vitro [58]. TRPV1 receptors regulate calcium influx to trigger apoptosis via the mitochondrial intrinsic and p38 MAPK-dependent pathways (Figure 1) [75]. TRPV1 also degrades EGFR (epidermal growth factor receptor), which is known to be overexpressed and activated in a variety of cancers; findings that highlight the tumour-suppressor capabilities of TRPV1, as well as identifying a role for CBD in cancer cell types where EGFR is overexpressed or mutated [76]. Commensurate with the tumour-suppressor capabilities of TRPV1, the expression of TRPV1 has been shown to be significantly decreased in the high-grade glioma, glioblastoma multiforme (GBM), thereby potentially reducing the therapeutic benefits of CBD in advanced patients [75]. In addition to TRPV1, TRPV2 plays a role in regulating glioma cell survival and proliferation, with high levels of TRPV2 expression detected in benign astrocytes, with progressively less expression of TRPV2 in high-grade gliomas corresponding with histological grade [77]. Indeed, the repression of TRPV2 abundance in human glioma cell lines was in turn demonstrated to result in the increased expression of cyclin E1, cyclin-dependent kinase 2 (CDK2), transcription factor E2F1 (E2F1), RAF proto-oncogene serine/threonine-protein kinase (RAF1) genes, and the anti-apoptotic gene, Bcl-xL (BCL2L1) [58]. Increased cyclin E1, CDK2, E2F1, RAF1 and BCL2L1 gene expression reduced the abundance of the cell death receptors and of proteins encoded by apoptosis-related genes, Fas and procaspase-8, an expression change that enhanced cell survival and proliferation (Figure 1). Interestingly, CBD has also been shown to enhance the cytotoxicity of certain chemotherapeutics via triggering TRPV2-dependent calcium (Ca2+) influx, and this in turn increased the degree of chemotherapeutic uptake, while simultaneously reducing the incidence of chemo-resistance in GBM cells. No such effect has been reported for normal human astrocytes.
(Table 1) [58]. A limitation of this study is, however, that parallel assessment of the TRPV2-dependent Ca$^{2+}$ influx and sensitisation to temozolomide (TMZ), carmustine (BCNU) or doxorubicin (DOXO) was not performed following Δ$^9$-THC treatment.

Figure 1. Transient receptor potential channels of the vanilloid subtype proteins and G-protein-coupled receptors mediates the anti-cancer effects of non-tetrahydrocannabinol (non-THC) cannabinoids. Cannabidiol (CBD) antagonises the de-orphaned G-protein-coupled receptor GPR55, and agonise transient receptor potential vanilloids (TRPVs), TRPV1 and TRPV2. CBD may out-compete the natural ligands of orphaned G-protein-coupled receptors (GPCRs), GPR3, GPR6 and GPR12, and this in turn suggests a mechanism for the inhibition of tumour growth and the induction of cell cycle arrest, and/or may even promote selection of cancer stem cells (CSCs).

3.2.2. De-Orphaned G-Protein-Coupled Receptor 55

GPR55 is widely expressed in the mammalian brain with its abundance concentrated in large dorsal root ganglions (DRGs) [78], and is also expressed in peripheral tissues such as the endocrine pancreas [79]. GPR55 is a direct target of the pCBs, CBD and Δ$^9$-THC, the eCBs, AEA and 2-AG, and the sCB, JWH-015 [63,80]. The downstream effects of GPR55 agonism depend on the cannabinoid present. For example, Δ$^9$-THC, AEA, JWH-015, bind GPR55 to drive intracellular release of Ca$^{2+}$ in HEK293 cells, transiently transfected to express human GPR55 (GPR55-HEK293), with this process regulated by G protein, G$_q/11$-phospholipase C (PLC) [77]. This effect can be abolished via the transient transfection of HEK293 cells with a dominant-negative mutant of G$_q/11$, or via use of the CB1R/GPR55 antagonist, SR141716A [78]. On the other hand, CBD, WIN-55,212–2 or 2-AG, all failed to increase the intracellular release of Ca$^{2+}$, with the CB2R antagonist, SR144528, also failing to reduce the degree of induction of JWH-015-mediated Ca$^{2+}$ flux in large DRG neurons. Additional GPR55-HEK293 transgenic studies showed that the inverse agonist of CB1R, AM251, and l-α-lysophosphatidylinositol (LPI; a ligand of GPR55), evoked GPR55-mediated Ca$^{2+}$ oscillation [81]. The endogenous lysophospholipid, LPI, is a well-established mitogenic mediator of oncogenic signalling [82,83]. LPI binding to GPR55 drives the proliferation of cancer cells, often in an autocrine fashion (reviewed in [84]), via the activation of the G protein-RhoA/Rho kinase (Rho/ROCK)-PLC signalling axis, resulting in intracellular Ca$^{2+}$ release from the endoplasmic reticulum (ER). This leads to the activation and subsequent nuclear translocation of the
transcription factor NFAT (nuclear factor of activated T-cells), which in turn regulates the transcriptional activity of a number of genes [81]. LPI-mediated Ca\(^{2+}\) release was abolished using the Rho/ROCK inhibitor, Y-27632, or by transiently transfecting GPR55-HEK293 cells with a dominant-negative mutant of RhoA [81].

These ground-breaking studies have laid the foundations for future research characterising the role GPR55 plays in cancer cell proliferation and anchorage-independent growth [85], angiogenesis [86], migration [87] and metastasis [88,89], with evidence that LPI-induced GPR55 activation plays a role in prostate, ovarian, GBM, breast, skin and pancreatic cancers (reviewed in [84]). Indeed, LPI (10 \(\mu\)M) induced activation of GPR55 in prostate and ovarian cancer cell lines drives the rapid intracellular release of Ca\(^{2+}\) to increase phosphorylation of the extracellular signal-regulated kinases, ERK and Akt [85]. Topically, LPI-induced ERK signalling was reduced by pre-treating human ovarian and prostate cancer cell lines with CBD (3.0 \(\mu\)M/0.94 mg/L), or SR141716A (2.0 \(\mu\)M), the Rho/ROCK inhibitor Y-27632 (20 \(\mu\)M), or via the molecular inhibition of GPR55 [84]. Interestingly, unlike CBD and SR141716A treatments, the inhibition of Rho/ROCK did not reduce LPI induced Ca\(^{2+}\) oscillation [84]. This finding recognises an important role for CBD in cancer cell types characterised by high GPR55 activity.

Elevated GPR55 gene expression in breast cancer is associated with reduced disease-free survival, overall survival, and metastasis-free survival, with the highest levels of expression observed in aggressive basal/triple-negative breast tumours [89]. Pro-metastatic properties in this context were exacerbated through an LPI-induced GPR55-G\(_{q11}\) coupling, and activation of RhoA, leading to actin cytoskeleton remodelling, changes in cell dynamics, and increased metastasis. Further, ERK activation in turn stimulates the expression of the transcription factor, ETV4/PEA3 [89] (Figure 1); a gene expression pattern associated with a higher risk of distant metastasis in basal/triple-negative breast cancers [90]. Importantly, previous studies have shown that CBD (5 mg/kg) inhibits the growth of MDA-MB-231 breast cancer cells in vivo using xenograft mouse models [13], once again highlighting a potential role for CBD in the treatment of GPR55 overexpression and aggressive cancer types.

Recently, using the KPC mouse model of pancreatic ductal adenocarcinoma (PDAC), Ferro et al. demonstrated that GPR55 signalling could enhance pancreatic cancer cell growth and proliferation in vivo, via the activation of the mitogen-activated protein kinase (MAPK) signalling pathway (Figure 1) [91]. The knockdown of GPR55, or its pharmacological inhibition using CBD, reduced ERK and ribosomal protein S6 phosphorylation, to decrease anchorage-dependent and -independent growth. In addition, inhibition of GPR55 using CBD decreased cyclin D1 and D2 expression and activated the tumour suppressor retinoblastoma (RB) to block cell cycle progression (Figure 1) [91]. The standard of care chemotherapy for pancreatic cancer centres on the use of the nucleoside analogue gemcitabine (GEM), which has previously been shown to increase ERK activation, a suggested mechanism of acquired resistance [92]. GEM can act via inhibition of the enzyme ribonucleotide reductase 1 (RRM1), and resistance to GEM can also be associated with increased RRM1 and RRM2 expression (Figure 1). The expression of both reductases however, was shown to reduce following CBD treatment in vitro [91]. Importantly, treatment using CBD (100 mg/kg), to inhibit GPR55, in combination with GEM (100 mg/kg), improved the survival rate of a PDAC mouse model by a factor of three (mean 52.7 vs. 18.6 days, median 56 vs. 20 days), compared to the vehicle control, and also longer than mice given GEM alone (mean 52.7 vs. 27.8 days, median 56 vs. 23.5). Furthermore, this combined treatment approach, when applied in vitro and in vivo, was also demonstrated to counteract the development of resistance to GEM [91], offering an exciting clinical prospect for the application of CBD in this setting.

3.2.3. Orphan G-Protein-Coupled Receptors GPR3, GPR6 and GPR12

Recently, it was shown that the constitutively active orphan GPCRs; GPR3, GPR6 and GPR12 (GPCRs phylogenetically related to the CBRs, CB1R and CB2R), are novel and specific targets of CBD [93]. These receptors are predominantly expressed in the brain and reproductive tissues, with the binding of CBD to GPR3, GPR6 and GPR12 thought to act as an inverse agonist of the unknown natural ligand of these orphan receptors [93,94]. GPR3 is overexpressed in breast cancer stem cells (CSCs). The inhibition of GPR3 activity in CSCs has been demonstrated to result in the enhanced
expression of the transcription factor encoding loci, NANOG, and OCT3/4 [95]. Both NANOG and OCT3/4 play central roles in promoting the self-renewal and long-term proliferative potential of stem-like cancer cells. It is therefore possible that CBD out-competes the endogenous ligand of these orphan GPCRs, thereby blocking β-arrestin2 recruitment to GPR3 and GPR6 [93,94]; an obstruction that would significantly decrease cAMP accumulation and reduce PKA signalling to inhibit the motility, growth and metabolism of the cell [96] (Figure 1). Conversely, CBD may block natural orphaned GPCR signalling, potentially leading to the enrichment of chemotherapy-resistant breast CSCs. Therefore, future research is required to adequately functionally characterise whether the interactions between CBD and these novel receptors, does in actual fact, portend an effective anti-cancer prospect.

3.3. Crosstalk between GPCRs and Non-GPCR Signalling Pathways

There is clear evidence that cannabinoids, particularly ∆9-THC, modulate the activity of GPCRs, including the well characterised CB1R and CB2R. However, conjecture remains about which downstream pathway(s) elicit the anti-cancer activity of CBD. While most studies have demonstrated that CBD has low affinity for CB1R and CB2R, research by McKallip et al. and Massi et al. revealed that in lymphoma and acute lymphoblastic leukaemia (ALL) cell lines and human glioma cell lines, respectively, CBD (2.5 μM/0.8 mg/L) induced apoptosis through a CB2R-specific mechanism, and not via binding to either CB1R or TRPV1 [51,97] (Figure 2). Furthermore, the treatment of primary T-ALL lymphoblasts with the CB2R selective agonist, JWH-133, and of Jurkat cells with the TRPV1 agonist, RTX, also induced apoptosis [98]. Whether the CBD effects in this context are a result of the level of CBR activity in these cells is yet to be unequivocally determined. However, additional in vitro research has shown that CBD inhibits human breast cancer cell growth and induces apoptosis via the activation of both CB2R and TRPV1 [13]. Taken together, these findings put forth the hypothesis that crosstalk between the GPCRs and non-GPCR signalling pathways may direct the selective anti-cancer activity of cannabinoids.

*Figure 2.* Cannabinoid induced anti-cancer crosstalk between G-protein-coupled receptor (GPCR) and non-GPCR signalling pathways is significant and complex. Cannabinoids interact with CB1R and CB2R and with non-cannabinoid receptors (CBRs) GPCRs (discussed in Section 3.3) to induce cancer cell death via promotion of cellular stress response pathways, increased ceramide synthesis, and reduced oncogenic growth and proliferation signalling.
Further evidence of crosstalk between oncogenic signalling pathways and either CB1R or CB2R is highlighted by the observation that Δ⁹-THC, WIN-55,212-2 or JWH-133, can downregulate the vascular endothelial growth factor receptors (VEGFRs), to reduce the angiogenesis and metastasis of skin cancer cells in vivo [99], and of glioma cells in vitro and in vivo [100] (Figure 2). The eCBs, AEA and 2-AG, and the sCB, HU-210, inhibit the proliferation of human breast and prostate cancer cells via crosstalk between the CB1R, the high-affinity nerve growth factor receptor (NTRK1) and the prolactin receptor (PRLR) signalling pathways [53] (Figure 2). In oestrogen receptor-α negative (ERα-) and positive (ERα+) breast cancers, the activation of CB2R by JWH-015 reduced breast cancer cell survival via blocking of the EGFR and insulin-like growth factor-1 receptor (IGF1R) pathways. Blockage of the EGFR and IGF1R pathways in turn leads to the reduced activation of the downstream signal transducer and activator of transcription 3 (STAT3), RAC-α,β,γ, Akt and ERK signalling pathways [101] (Figure 2). Interestingly, positive correlation between elevated CB2R expression and relapse-free survival has been established [53]. This positive correlation is particularly evident in ERα+ and ERα- breast cancer patient samples, cancer cell types known to have elevated EGFR and IGF1R expression [53]. Such observations may support the potential use of CB2R agonists as an adjuvant therapy option for ERα+ and ERα- breast cancer patients [101].

CBD has been shown to be effective alone, and in combination with the approved proteasome inhibitor, bortezomib, for the treatment of multiple myeloma (MM) [60]. In this context, TRPV2 was shown to regulate the cytotoxic effects of CBD, in a TRPV2 expression dependent manner [60]. TRPV2 activation by CBD decreased the levels of phosphorylation of ERK and Akt, and synergised the effects of bortezomib treatment, to decrease cyclin D1 (CCND1) expression. More recent studies highlighted the crosstalk between CB1R-dependent and independent anti-cancer effects induced by cannabinoids in MM. For example, Nabissi et al. further revealed that CBD was able to arrest the growth and survival of MM cell lines by halting the cell cycle at the G1 phase, but also showed that Δ⁹-THC was an additional effective cell cycle inhibitor, a finding that further highlights a role for Δ⁹-THC in TRPV2 activation [61]. These studies showed that a 1:1 combination of CBD and Δ⁹-THC was statistically more effective at increasing the G1 cell population, compared with either CBD or Δ⁹-THC treatment alone [61], effects not antagonised via the use of the CB2R antagonist, AM630. Interestingly, rather than activating apoptotic cascades, autophagic cell death was induced following combination treatment with Δ⁹-THC and CBD. These studies went on to show reduced migration and down-regulation of the chemokine receptor, CXCR4, and of the CD147 plasma membrane glycoprotein, using CBD or Δ⁹-THC alone (CBD 12.5 μM/3.9 mg/L, Δ⁹-THC 12.5 μM/3.9 mg/L), Δ⁹-THC:CBD in combination, the immuno-proteasome inhibitor carfilzomib (100 nM) alone, and the combined treatment with all three compounds. The results of these preclinical studies have recently prompted investigators to commence a randomised, double-blind, placebo-controlled clinical trial to investigate whether combination of CBD with bortezomib will have greater anti-tumour and anti-proliferative activity compared to standard of care (bortezomib alone) in MM, GBM and gastrointestinal (GI) malignancies (Table 2).

The crosstalk between non-THC cannabinoids and the modulation of the GPCR-dependent, and GPCR-independent signalling pathways, is becoming more evident. However, there remains an urgent need for the application of a more focused research approach that are based on the use of purified non-THC cannabinoids and the ‘simulated’ assessment of downstream effects using whole proteome data [102], with the elegant supplementation of phosphoproteome data [103]. The heterogeneity of cancer is such that, until the field acquires a more detailed understanding of the downstream effects of both Δ⁹-THC and non-THC cannabinoids, unlocking the definitive and selective anti-cancer mechanisms of action of these compounds will remain ambiguous, and continue to limit their clinical utility.

### 3.4. Cannabinoid Receptor-Dependent Cancer Effects

There is growing evidence that cannabinoids inhibit tumour growth and metastasis and induce tumour-specific apoptosis in cancer cells following the activation of CB1R or CB2R (Figure 3) [39,47,104]. Although counterintuitively, it is generally recognised that high grade gliomas, such as GBMs, express...
high levels of CB2R, with the degree of CB2R expression correlating with tumour grade (reviewed in [105]). However, the data remains unclear for CB1R. In GBM tissue, compared to low-grade gliomas, or non-tumour control tissue, De Jesús et al. revealed reduced expression of CB1R [106], Schley et al. determined that CBR1 expression remained unchanged [107], and Wu et al. [108] and Ciaglia et al. [109] found CBR1 expression to be elevated (reviewed in [110]). In the most aggressive and lethal of all children’s cancers, diffuse intrinsic pontine glioma (DIPG), the picture is even more unclear [111]. The abundance and/or activity of these two receptors is more clearly reported in astrocytoma, meningioma, non-small-cell lung carcinoma (NSCLC) and lymphoma, as well as skin, prostate, breast and colon cancers (reviewed in [14]). Taken together, these findings potentially highlight the use of Δ9-THC and CBD to elicit cancer selective cell death via CBR-dependent and -independent mechanisms, respectively. However, there is a distinct difference between the stimulatory and inhibitory activities of these receptors, a difference that predominantly depends on the agonist, and on the cancer cell line used [112]. The binding of Δ9-THC to CB1R or CB2R reduces cancer cell survival by inducing a stress response driving ceramide production, which in turn modulates growth and proliferation signal transduction cascades, to activate both extrinsic and intrinsic caspases (Figure 3) [47,112]. The CB1R and CB2R agonist, Δ9-THC, inhibits cell growth by sustained ceramide accumulation, and via the activation of ERK, c-Jun N-terminal kinase (JNK) and p38 MAPK [69,113]. Treatment with CBR agonists, WIN-55,212-2, JWH-015 and JWH-133, also inhibits the growth and metastasis of NSCLC in vitro and in vivo by inhibiting Akt phosphorylation and reducing matrix metalloproteinase-9 (MMP9) expression and activity. This in turn inhibits the reorganisation of the extracellular matrix, as well as to also inhibit the migratory potential of malignant cells [114].

**Figure 3.** Anti-cancer effects and cell death pathways regulated by cannabinoids and the classical cannabinoid receptors. The activation of cannabinoid receptors (CBRs) drives sustained extracellular signal-regulated kinases (ERK) activity driving reactive oxygen species (ROS) production and leads to activation of cyclin kinase inhibitors resulting in G1 cell cycle arrest [45,115]. Agonism of cannabinoids receptors increases ceramide synthesis to induce endoplasmic reticulum (ER) stress driving phosphorylation and activity of the transcription factor eukaryotic translation initiation factor 2A (eIF2α), leading to upregulation of p8 and its downstream targets cyclic AMP-dependent transcription factor ATF-4 (ATF4), C/EBP homologous protein (CHOP), and tribbles homolog 3 (TRIB3). Activation of p8 inhibits the Akt/mTORC1 axis, driving autophagy-mediated cell death pathway upstream of apoptosis [116].
As alluded to in Section 1, ‘not every cloud has a silver lining’, with ∆⁹-THC exposure demonstrated to promote mouse mammary tumour growth and metastasis, due to its role in reducing the specific anti-tumour immune responses of immune cells known to express high levels of CB2R [8]. Importantly, the agonism of CBRs using nanomolar concentrations of ∆⁹-THC increased the proliferation of cancer cells through activation of MAPK via transactivation of EGFR [117]. These pro-survival (cancer propagating) effects are also seen for AEA and the sCBs, HU-210 and WIN-55,212-2 [117]. The concentration of ∆⁹-THC in this context is likely to reflect serum levels detected after ∆⁹-THC administration and hence are therapeutically relevant. At the current time, the prosurvival effects seen for ∆⁹-THC have not been reported for CBD. Whether this is a result of lack of CBD affinity for CBRs, particularly in immune cells, or whether pro-survival signalling requires CBR-induced transactivation of receptor tyrosine kinases, activation that is not possible following the administration of CBD due to CBD lacking affinity for CBRs, remains to be tested.

3.4.1. Cannabinoids Induce Apoptosis via Sustained Ceramide Accumulation

Numerous reports have shown that the modulation of CBR activity by cannabinoids inhibits the in vitro and in vivo growth and survival of cancer cells via the production of ceramide, a pro-apoptotic sphingolipid [49,69,118–120]. CBR activation by either ∆⁹-THC or WIN-55,212-2 drives the intracellular accumulation of ceramide to activate Raf1/ERK signalling, which in turn leads to the production of damaging cellular reactive oxygen species (ROS) (Figures 2 and 3). This drives genotoxic stress and apoptosis in glioma cells, both in vitro and in vivo [69]. Ceramide accumulation leads to ER stress, which in turn enhances the expression of the stress-regulated protein, p8, with enhanced p8 abundance leading to the inhibition of the Akt/mammalian target of rapamycin (mTOR) cell signalling axis and the activation of caspase cascades to drive apoptosis and autophagy [2,121]. Likewise, the increased expression of cellular tumour antigen, p53 (TP53), and of the apoptosis regulator, BAX (BAX), plus the reduced expression of anti-apoptotic protein Bcl-2, (BAD), have all been demonstrated in cervical cancer cells treated with cannabis extracts or purified CBD (Figure 2) [46]. Additional reports show that in human colon cancer cell lines, activation of the individual and specific activities of certain CBRs induces apoptosis through a tumour necrosis factor-α (TNF-α) mediated de novo synthesis of ceramide [49].

3.4.2. Downstream Targets of Ceramide

The ceramide-dependent upregulation of stress-regulated protein, p8, is a hallmark of treatment of glioma, astrocytoma, and pancreatic cancer cells with cannabinoids [119]. ER stress drives phosphorylation and activity of the transcription factor, eIF2α, leading to upregulation of p8 and of the downstream proteins, including CAMP-dependent transcription factor, ATF-4, C/EBP homologous protein, CHOP, and pseudokinase tribbles-homologue 3, TRIB3, which sensitises tumour cells to ∆⁹-THC treatment and leads to cell death via autophagy and apoptosis (Figures 2 and 3) [116,121]. It is important to note here that Akt dysfunction is one of the most common molecular events in cancer. Increased TRIB3 activity inhibits the Akt/mTOR signalling axis to trigger autophagy (upstream of intrinsic mitochondrial apoptosis), and further, decreased Akt activity together with increased BAD activity, directs the activation of cyclin-dependent kinase inhibitor 1A (CDKN1A) and CDKN1B (reviewed in [2]).

CBD and ∆⁹-THC induced apoptosis in vitro and in vivo using human breast [122] and leukaemic cells [51,120] has been shown to be regulated by ceramide biosynthesis. Ceramide reduces mitochondrial membrane potential by the translocation of BH3-interacting domain death agonist protein, BID, to the mitochondria to release the small hemeprotein, cytochrome C (CYC1) to the cytosol, ultimately activating intrinsic apoptotic pathways via the caspase cascade (CASP8, CASP9, and CASP3) [120,123] (Figure 2). The overlap between apoptosis and autophagy is potentially regulated by Beclin-1 (BECN1); CBD enhanced the interaction between BECN1 and phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), as this protein-protein interaction cross-regulates the instigation of autophagosomes,
and the activation of apoptosis, through direct interactions with anti-apoptosis family members Bcl-2 and/or Bcl-xL (reviewed in [124]). In short, CBR-induced cancer cell death relies on ceramide-induced ER stress and the upregulation of p8 driving caspase cascade activation (Figure 3).

3.4.3. Cannabinoid Induced Anti-Cancer Effects

A trademark effect of the treatment of cancer cells with both the pCBs, CBD and Δ9-THC, and the eCBs, AEA and 2-AG, is the production of ROS, resulting in increased cellular oxidative stress [125–127]. Indeed, CBD drives ROS production to deplete the intracellular stores of glutathione (GSH), and triggers the activity of GSH-associated enzymes such as glutathione peroxidases and glutathione reductases, to activate the pro-apoptotic proteins, caspase-8 (CASP8) and CASP9 (CASP9) (Figure 3). Elevated CASP8 and CASP9 abundance within a cancer cell promotes the cleavage of CASP3 (CASP3), and this in turn, leads to cell death [97,122,127]. However, supplementation with the antioxidant, α-tocopherol, rescues the cytotoxic effects of AEA and 2-AG [125]. Indeed, treatment of human ALL cells with CBD promotes the expression and activity of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) subunit, NOX4 (NOX4), and its regulatory protein, p22phox (CYBA) [51]. Activated NOX4 is responsible for directing the ‘respiratory burst’ (the rapid release of ROS) required for the destruction of invading microbes (reviewed in [128]). CBD-induced ROS production, and hence increased oxidative stress, decreases the phosphorylation status of p38 MAPK to direct apoptosis (Figure 2). In line with these observations, treatment of ALL cells with the CB2R-selective antagonist, SR144528, NADPH oxidase inhibitors, or ROS scavengers, significantly attenuated apoptosis induced by CBD [51]. In direct contrast, Δ9-THC used in animal models to study the human immunodeficiency virus (HIV), decreased NOX4 expression, which in turn reduced the levels of cellular oxidative stress in intestinal cells, via upregulation of the abundance of the NOX4 targeting microRNA, miR-99b, thereby decreasing the rate of translation of the NOX4 protein [129].

In addition, Olivas et al. showed that in T-ALL cells sensitive to CBD, cell death was not influenced by CBRs [130]. Autophagy was activated by sub-lethal CBD concentrations by Ca2+ overload in the mitochondria, releasing cytochrome-C, and potentially highlighting a role for GPR55 in this context. It is well documented that the anti-inflammatory effects of Δ9-THC in the gastrointestinal tract are predominantly mediated by modulating CB2R activity, and therefore, the pro-oxidative effects of CBD may not strictly be the result of the antagonism of CB2R, but of crosstalk, or independent activation of non-CBRs GPCRs or ion channels.

Apoptosis induced by CBD in lung cancer cells has also been shown to be independent of CB1R or CB2R activity [52]. CBD treatment-induced expression at both the mRNA and protein level of the nuclear receptor, and transcription factor, peroxisome proliferator-activated receptor gamma (PPAR-γ (PPARG)) and of the cyclooxygenase-2 (COX-2 (prostaglandin G/H synthase 2–PTGS2)) transcript/protein [130]. Apoptosis was abrogated by the use of COX-2 inhibitors and PPAR-γ antagonists in lung cancer cell lines, primary lung cancer patient samples, and in vivo, using athymic nude mice xenografted with the lung cancer cell line A549 (Figure 2). CBD has been shown to directly bind PPAR-γ to increase its transcriptional activity [131]. These findings suggest that COX-2 and PPAR-γ are critical for the anti-cancer effects of CBD in lung cancer and provide strong evidence that the molecular targets of CBD may at least be, in part, dependent on the cancer cell type being treated.

4. Clinical Evidence: Cannabis for Use by Patients with Cancer

Pre-clinical studies investigating the potential anti-cancer properties of cannabis (and of cannabinoids) have rekindled clinical interest in their use for the treatment of various cancer types (Table 2) [110,132]. Whilst significant in vitro and in vivo research is currently underway, there are only a limited number of clinical trials investigating the potential of low-THC cannabis or non-THC cannabinoids for the treatment of cancer. That being said, the long-term risk-benefit ratio for the use of CBD is yet to be determined, especially in the adolescent population. Research on cannabinoid:drug
interactions are also urgently needed and will provide the necessary pharmacokinetic and toxicological parameters for future treatment strategies.

In an uncontrolled retrospective case-series of 119 breast cancer and/or glioma patients who received synthetic, pharmaceutical-grade CBD alone, or in combination with other treatments, synthetic CBD was well tolerated and not limited by a maximal tolerated dose. Measures of anti-cancer efficacy included a reduction in circulating tumour cells or a radiological response, and while most claims of benefit could be related to interpatient variation or cancer heterogeneity, occasional extraordinary responders were noted, including two patients with ependymoma [132]. The average dose of CBD was 10 mg twice daily, administered via a three day on/three day off rotation. Such an administrative approach was achieved in the complete absence of any notable side effects. An extended median overall survival rate of 36% was observed for patients on this regimen, with 24% of these patients administered CBD only. A separate group of nine GBM patients received a daily dose of 400 mg CBD (approximately 6.5 mg/kg), alongside standard of care including maximal resection followed by radiochemotherapy [133]. Of the nine GBM patients in this treatment group, eight patients were alive with a mean survival of 22.3 months, almost two-fold the median overall survival for GBM patients.

Additionally, an unpublished and underpowered phase II trial study in recurrent GBM patients treated with a 1:1 ratio of Δ⁹-THC:CBD (27 mg/mL and 25 mg/mL) in combination with temozolomide, reported an increased 1-year overall survival rate of 83%, compared to 44% for patients treated with temozolomide alone (p = 0.042) (reviewed [110]). Such a promising result was accompanied by treatment emergent adverse events, including vomiting (75%), dizziness (67%) nausea (58%), headache (33%), and constipation (33%), compared to limited, or no, adverse events in emerging clinical investigations using CBD alone [132].

5. Role of Non-THC Cannabinoids in Cancer-Associated Inflammation

The relationship between inflammation and the evolution of certain cancer types is thoroughly established. Up to 20% of cancer associated deaths worldwide are related to cancer-induced inflammation [67]. There is emerging evidence to suggest that cannabinoids induce apoptosis of inflammatory, or of other immune cell types, via CBR activation. Ligation of cannabinoids with CB2R has been demonstrated to function as a potent regulator of immune responses due to its abundance in all immune cell subtypes, including B cells, T cells and NK (natural killer) cells [67]. Agonist binding to CB2R drives immunosuppression through the inhibition of adenylyl cyclase (AC), which in turn, downregulates the cAMP signal transduction pathways and the activity of cAMP-dependent kinases (PKA) [134,135]. Likewise, in human monocytes and macrophages, CB2R activation directs the decreased production of the pro-inflammatory cytokines, interleukin-6 (IL-6), IL-8, IL-12 and TNFα [134]. Elbaz et al. reported that breast cancer cells treated with CBD have reduced levels of inflammatory cytokines, such as C-C motif chemokine 3 (CCL3), granulocyte-macrophage colony-stimulating factor GM-CSF (CSF2), and macrophage inflammatory protein 2 (MIP-2), as well as decreased recruitment of macrophages to the tumour microenvironment [136]. Similarly, CBD has exhibited protective effects in intestinal inflammation and has been demonstrated to inhibit the release of cytokines and to promote wound healing [137].

It is important to consider the immunomodulatory effects of cannabinoids when considering their combined use with anti-cancer immunotherapies, including the checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1), or with cellular therapies such as chimeric antigen receptor T-cells (CAR-T), particularly for regimens including Δ⁹-THC. A recent retrospective, observational study of patients with either advanced melanoma (NSCLC), or renal cell carcinoma, showed that study participants who received nivolumab (an anti-PD-1 therapy), in combination with an unspecified cannabis product, had lower response rates (RR) to nivolumab, compared to those receiving nivolumab alone (i.e., 15.9% compared to 37.5%; odds ratio [OR] 3.13, p = 0.016) [9]. Interestingly, patients who included cannabis as part of their immunotherapy treatment regimen showed no significant differences in either progression-free survival (p = 0.27) or overall survival (p = 0.45) [9], even though this patient
cohort did not respond to nivolumab. This finding presents a curious question, that being; why did cannabis patients that failed to respond to immunotherapy, survive just as long as those patients who responded to immunotherapy? Deciphering the clinical benefit from the use of cannabinoids through the inclusion of a ‘cannabis/cannabinoid treatment’ alone, or ‘cannabis in combination with standard-of-care chemotherapies’ may greatly aid in the clinical utilisation of cannabis when targeting the immune system as a frontline treatment strategy.

6. Conclusions

There is a clear imperative to improve the treatment of cancer, particularly for cancers lacking effective treatment options. New immunotherapeutic approaches are dramatically increasing the survival of patients with advanced disease states, such as those patients with metastatic melanoma; where previously survival was measured in months. However, sophisticated immunological or cell-based treatment approaches are yet to be developed (or are not always viable) for high-risk or advanced cancers, including relapsed acute myeloid leukaemia (AML) [138], or high-risk T-ALL [103]. Similarly, paediatric patients with highly aggressive brainstem cancers, such as DIPG or DMG, progress soon after upfront radiotherapy. This standard of care regimen is accompanied by peritumoural inflammation and hydrocephalus [111], and represents a patient cohort with greatly unmet therapeutic needs: the opportunity to employ complementary therapeutics (that specifically lack psychotropic side effects) to enhance or complement standard of care management of high risk, aggressive cancers warrants intensive investigation.

Several pre-clinical and clinical investigations have focused on the anti-cancer potential of cannabis and its constituents, namely CBD and Δ⁹-THC, and are beginning to reveal novel therapeutic potentials. Nevertheless, in addition to social and legal complexities, the serious side effects associated with the use of Δ⁹-THC (particularly in children and elderly patients) are a major roadblock in the use of cannabis in the medical setting. Consequently, research and consumer interest in low-THC cannabis can deliver an alternative to traditional cannabis, including an alternate treatment route (oral dosing), and has gained considerable momentum recently. Unfortunately, research focused on the anti-cancer properties of low-THC cannabis, and of its major pharmacologically active components, such as CBD, are slow to reach clinical studies. Most of the available literature remains limited to reports of the pre-clinical efficacy of low-THC cannabis. As a result, a comprehensive and clear picture of the mechanisms driving the anti-cancer properties of low-THC cannabis, and of non-THC cannabinoids, remains a work in progress.

Consistent lines of evidence show that cannabinoids play a role in modulating neural and immune functions, both centrally and peripherally, via the classical CB1R and CB2R mediated receptor routes, particularly for Δ⁹-THC, while CBD is more commonly reported to function as a ligand for other GPCRs (including GPR55, GPR3, GPR6, GPR12, TRPVs and PPAR-γ). While the exact mechanistic basis remains unclear, there appears to be significant crosstalk between the molecular targets of cannabinoid responsive pathways, targets which could ultimately determine downstream proliferation or anti-tumour responses. If this was not complicated enough; the use of cannabis plant extracts, which are generally highly complex mixtures of cannabinoids, terpenoids and other bioactive natural products, makes identification of the anti-cancer benefits even more challenging. That being said, studies generally show that pure CBD is superior to CBD-rich extracts and other plant cannabinoids (CBG, CBC) for inhibition of tumour cell growth and survival, and without any cytotoxic effect on healthy cells, at the doses reported (IC50: 6–10 µM/1.9–3.1 mg/L) [139]. While the application of low-THC cannabis extracts may prove beneficial as an alternate cancer treatment in the future, owing to the potential cooperative nature of its diverse chemical components (entourage effect), conversely, it could also undermine efficacy and foster the development of drug resistance to established chemotherapeutic protocols. More data is still urgently needed to establish the ‘pros’ and ‘cons’ of using whole cannabis extracts, or isolated cannabinoids, before its application in clinical trial settings.
There is a strong and compelling case for further mechanistic studies into the potential anti-tumour and related health benefits of low-THC cannabis. Proteogenomic studies [140], and studies focused on cellular responses to cannabinoids [141], will ultimately provide mechanistic data to determine whether CBD and other non-THC cannabinoids can be included as safe, alternative treatment strategies to those currently investigating $\Delta^9$-THC-based strategies in the clinic. Given that a number of the chemical components of low-THC cannabis interact with several critical molecular targets, and that these targets repeatedly demonstrate an altered expression and/or accumulation profile in cancerous cells, further research into the anti-cancer properties of medicinal cannabis, could lead to the discovery of effective treatments and deliver further invaluable insight into cancer cell biology for researchers, clinicians and patients alike.

**Author Contributions:** M.C., F.A., A.S.W., M.D.D. wrote the manuscript, generated the Figures and Tables. A.L.E., R.J.D., A.M.D., J.S., C.G., A.S.W. and M.D.D. reviewed and revised the manuscript. All authors have read and agree to the published version of the manuscript.

**Funding:** M.C. and M.D.D. are supported by a Cancer Institute N.S.W. Fellowships. M.D.D. is supported by an NHMRC Investigator Grant, and the University of Newcastle. This study was supported by the Australian Natural Therapeutic Group (ANTG), the Hunter Medical Research Institute (HMRI), RUN DIPG, the Cancer Institute NSW (CINSW), and the National Health and Medical Research Council (NHMRC).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Zuardi, A.W. History of cannabis as a medicine: A review. *Braz. J. Psychiatry* 2006, 28, 153–157. [CrossRef] [PubMed]
2. Velasco, G.; Sanchez, C.; Guzman, M. Towards the use of cannabinoids as antitumour agents. *Nat. Rev. Cancer* 2012, 12, 436–444. [CrossRef]
3. Cui, W.; Howells, E.; Devitt, B. Medicinal cannabis: The knowledge, attitudes, and practices of Australian patients with cancer. In Proceedings of the Medical Oncology Group of Australia Annual Scientific Meeting, Canberra, Australia, 14–16 August 2019; p. 59.
4. Pacula, R.L.; Smart, R. Medical Marijuana and Marijuana Legalization. *Annu. Rev. Clin. Psychol.* 2017, 13, 397–419. [CrossRef]
5. Russo, E.B. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br. J. Pharmacol.* 2011, 163, 1344–1364. [CrossRef]
6. Carlini, E.A. The good and the bad effects of $\Delta(-)$-trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. *Toxicon* 2004, 44, 461–467. [CrossRef] [PubMed]
7. Condie, R.; Herring, A.; Koh, W.S.; Lee, M.; Kaminski, N.E. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. *J. Biol. Chem.* 1996, 271, 13175–13183. [CrossRef] [PubMed]
8. McKallip, R.J.; Nagarkatti, M.; Nagarkatti, P.S. $\Delta$-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J. Immunol.* 2005, 174, 3281–3289. [CrossRef] [PubMed]
9. Taha, T.; Meiri, D.; Talhamy, S.; Wollner, M.; Peer, A.; Bar-Sela, G. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. *Oncologist* 2019, 24, 549–554. [CrossRef] [PubMed]
10. Lile, J.A.; Kelly, T.H.; Charnigo, R.J.; Stinchcomb, A.L.; Hays, L.R. Pharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Delta(9) -THC in cannabis users. *J. Clin. Pharmacol.* 2013, 53, 680–690. [CrossRef]
11. Mechoulam, R.; Parker, L.A.; Gallily, R. Cannabidiol: An overview of some pharmacological aspects. *J. Clin. Pharmacol.* 2002, 42, 115–195. [CrossRef]
12. Scott, K.A.; Dalgleish, A.G.; Liu, W.M. Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. *Int. J. Oncol.* 2017, 51, 369–377. [CrossRef] [PubMed]
13. Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 2006, 318, 1375–1387. [CrossRef] [PubMed]

14. Sledzinski, P.; Zeyland, J.; Slomski, R.; Nowak, A. The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. 2018, 7, 765–775. [CrossRef] [PubMed]

15. Parliament of NSW. Hemp Industry Act 2008 No 58; Parliamentary Counsel’s Office: Sydney, Australia, 2017.

16. Parliament of Western Australia. Industrial Hemp Act 2004; Parliament of Western Australia: Perth, Australia, 2018.

17. Patel, B.; Wene, D.; Fan, Z.T. Qualitative and quantitative measurement of cannabinoids in cannabis using modified HPLC/DAD method. J. Pharm. Biomed. Anal. 2017, 146, 15–23. [CrossRef]

18. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research; The National Academies Press: Washington, DC, USA, 2017; p. 486. [CrossRef]

19. Shannon, S.; Lewis, N.; Lee, H.; Hughes, S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm. J. 2019, 23, 18–041. [CrossRef]

20. Thiele, E.; Marsh, E.; Mazurkiewicz-Beldzinska, M.; Halford, J.J.; Gunning, B.; Devinsky, O.; Checketts, D.; Roberts, C. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia 2019, 60, 419–428. [CrossRef]

21. Dall’Sella, P.B.; Docema, M.F.L.; Maldaun, M.V.C.; Feher, O.; Lancellotti, C.I.P. Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol. Front. Oncol. 2018, 8, 643. [CrossRef]

22. Imtiaz, S.; Shield, K.D.; Roerecke, M.; Cheng, J.; Popova, S.; Kurdyak, P.; Fischer, B.; Rehm, J. The burden of disease attributable to cannabis use in Canada in 2012. Addiction 2016, 111, 653–662. [CrossRef]

23. Mandelbaum, D.E.; de la Monte, S.M. Adverse Structural and Functional Effects of Marijuana on the Brain: Evidence Reviewed. Pediatr. Neurol. 2017, 66, 12–20. [CrossRef]

24. Gruber, S.A.; Sagar, K.A.; Dahlgren, M.K.; Gonenc, A.; Smith, R.T.; Lambros, A.M.; Cabrera, K.B.; Lukas, S.E. The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment. Front. Pharmacol. 2017, 8, 983. [CrossRef]

25. Gomez Del Pulgar, T.; De Ceballos, M.L.; Guzman, M.; Velasco, G. Cannabis use during pregnancy and its relationship with infant birth weight. J. Addict. Med. 2019, 13, 436–441. [CrossRef] [PubMed]

26. Lenzi, M.; Cocchi, V.; Caveda, L.; Bilel, S.; Hrelia, P.; Marti, M. Genotoxic Properties of Synthetic Cannabinoids on TK6 Human Cells by Flow Cytometry. Int. J. Mol. Sci. 2020, 21, 1150. [CrossRef] [PubMed]

27. Koller, V.J.; Ferk, E.; Al-Serori, H.; Miš, M.; Nersesyan, A.; Auwärter, V.; Grummt, T.; Knasmüller, S. Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids. Food Chem. Toxicol. 2015, 80, 130–136. [CrossRef] [PubMed]

28. Barbosa-Leiker, C.; Burduli, E.; Smith, C.L.; Brooks, O.; Orr, M.; Gartstein, M. Daily Cannabis Use During Pregnancy and Postpartum in a State With Legalized Recreational Cannabis. J. Addict. Med. 2020. [CrossRef] [PubMed]

29. Howard, D.S.; Dhanraj, D.N.; Devaiah, C.G.; Lambers, D.S. Cannabis Use Based on Urine Drug Screens in Pregnancy and Its Association With Infant Birth Weight. J. Addict. Med. 2019, 13, 436–441. [CrossRef] [PubMed]

30. Roncero, C.; Valriberas-Herrero, I.; Mezzatesta-Gava, M.; Villegas, J.L.; Aguilar, L.; Grau-Lopez, L. Cannabis use during pregnancy and its relationship with fetal developmental outcomes and psychiatric disorders. A systematic review. Reprod. Health 2020, 17, 25. [CrossRef] [PubMed]

31. Karila, L.; Roux, P.; Rolland, B.; Benyamina, A.; Reynaud, M.; Aubin, H.J.; Lancon, C. Acute and long-term effects of cannabis use: A review. Curr. Pharm Des. 2014, 20, 4112–4118. [CrossRef]

32. Zuardi, A.W.; Crippa, J.A.; Hallak, J.E.; Bhattacharyya, S.; Atakan, Z.; Martin-Santos, R.; McGuire, P.K.; Guimarães, F.S. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr. Pharm Des. 2012, 18, 5131–5140. [CrossRef]

33. Kis, B.; Ifrim, F.C.; Buda, V.; Avram, S.; Pavel, L.Z.; Antal, D.; Paunescu, V.; Dehelean, C.A.; Ardelean, F.; Diaconeasa, Z.; et al. Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer. Int. J. Mol. Sci. 2019, 20, 5905. [CrossRef]
34. Lucas, C.J.; Galettis, P.; Schneider, J. The pharmacokinetics and the pharmacodynamics of cannabinoids. *Br. J. Clin. Pharmacol.* 2018, 84, 2477–2482. [CrossRef]

35. Ewing, L.E.; Skinner, C.M.; Quick, C.M.; Kennon-McGill, S.; McGill, M.R.; Walker, L.A.; ElSohly, M.A.; Gurley, B.J.; Koturbash, I. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. *Molecules* 2019, 24, 1694. [CrossRef] [PubMed]

36. Pisanti, S.; Malfitano, A.M.; Ciaglia, E.; Lamberti, A.; Ranieri, R.; Cuomo, G.; Abate, M.; Faggiana, G.; Proto, M.C.; Fiore, D.; et al. Cannabidiol: State of the art and new challenges for therapeutic applications. *Pharmacol. Ther.* 2017, 175, 133–150. [CrossRef]

37. McPartland, J.M.; Russo, E.B. Cannabis and Cannabis Extracts Greater Than the Sum of Their Parts? *J. Cannabis Ther.* 2001, 1, 103–132. [CrossRef]

38. Turner, C.E.; Elsohly, M.A.; Boeren, E.G. Constituents of *Cannabis sativa* L. XVII. A review of the natural constituents. *J. Nat. Prod.* 1980, 43, 169–234. [CrossRef] [PubMed]

39. Chakravarti, B.; Ravi, J.; Ganju, R.K. Cannabinoids as therapeutic agents in cancer: Current status and future implications. *OncoTarget* 2014, 5, 5852–5872. [CrossRef] [PubMed]

40. Maccarrone, M. Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years. *Front. Mol. Neurosci.* 2017, 10, 166. [CrossRef]

41. Maccarrone, M.; Finazzi-Agro, A. The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. *Cell Death Differ.* 2003, 10, 946–955. [CrossRef]

42. Placzek, E.A.; Okamoto, Y.; Ueda, N.; Barker, E.L. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. *Neuropharmacology* 2008, 55, 1095–1104. [CrossRef]

43. Blankman, J.L.; Simon, G.M.; Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem. Biol.* 2007, 14, 1347–1356. [CrossRef]

44. Galve-Roperh, I.; Chiurchiu, V.; Diaz-Alonso, J.; Bari, M.; Guzman, M.; Maccarrone, M. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. *Prog. Lipid Res.* 2013, 52, 633–650. [CrossRef]

45. Sarfaraz, S.; Afaq, F.; Adhami, V.M.; Malik, A.; Mukhtar, H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. *J. Biol. Chem.* 2006, 281, 39480–39491. [CrossRef] [PubMed]

46. Lukhele, S.T.; Motadi, L.R. Cannabidiol rather than *Cannabis sativa* extracts inhibit cell growth and induce apoptosis in cervical cancer cells. *BMC Complement. Altern. Med.* 2016, 16, 335. [CrossRef] [PubMed]

47. Marcu, J.P.; Christian, R.T.; Lau, D.; Zielinski, A.J.; Horowitz, M.P.; Lee, J.; Pakdel, A.; Allison, J.; Limbad, C.; Ronconi, E.; Romagnani, P.; et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide de novo synthesis in colon cancer cells. *Blood* 2008, 112, 7691–7700. [CrossRef]

48. Cianchi, F.; Papucci, L.; Schiavone, N.; Lulli, M.; Magnelli, L.; Vinci, M.C.; Messerini, L.; Manera, C.; Ronconi, E.; Romagnani, P.; et al. Cannabinoid receptor activation induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. *J. Biol. Chem.* 2006, 281, 31938–31945. [CrossRef] [PubMed]

49. Cianchi, F.; Papucci, L.; Schiavone, N.; Lulli, M.; Magnelli, L.; Vinci, M.C.; Messerini, L.; Manera, C.; Romagnani, P.; et al. Cannabinoid receptor activation induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. *J. Biol. Chem.* 2006, 281, 31938–31945. [CrossRef] [PubMed]

50. McKallip, R.J.; Lombard, C.; Fisher, M.; Martin, B.R.; Ryu, S.; Grant, S.; Nagarkatti, P.S.; Nagarkatti, M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. *Blood* 2002, 100, 627–634. [CrossRef] [PubMed]

51. Placzek, E.A.; Okamoto, Y.; Ueda, N.; Barker, E.L. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. *Neuropharmacology* 2008, 55, 1095–1104. [CrossRef]

52. Blankman, J.L.; Simon, G.M.; Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem. Biol.* 2007, 14, 1347–1356. [CrossRef]

53. Galve-Roperh, I.; Chiurchiu, V.; Diaz-Alonso, J.; Bari, M.; Guzman, M.; Maccarrone, M. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. *Prog. Lipid Res.* 2013, 52, 633–650. [CrossRef]
54. Sultan, A.S.; Marie, M.A.; Sheweita, S.A. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. *Breast* 2018, 41, 34–41. [CrossRef] [PubMed]
55. Qamri, Z.; Preet, A.; Nasser, M.W.; Bass, C.E.; Leone, G.; Barsky, S.H.; Ganju, R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. *Mol. Cancer Ther.* 2009, 8, 3117. [CrossRef]
56. Borrelli, F.; Pagano, E.; Romano, B.; Panzera, S.; Maiello, F.; Coppola, D.; De Petrocellis, L.; Buono, L.; Orlando, P.; Izzo, A.A. Colon carcinogenesis is inhibited by the TRPMB8 antagonist cannabinigrol, a Cannabis-derived non-psychotropic cannabinoid. *Carcinogenesis* 2014, 35, 2787–2797. [CrossRef] [PubMed]
57. Singer, E.; Judkins, J.; Salomonis, N.; Mattaf, L.; Soteropoulos, P.; McAllister, S.; Soroceanu, L. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. *Cell Death Dis.* 2015, 6, e1601. [CrossRef]
58. Nabissi, M.; Morelli, M.B.; Santoni, M.; Santoni, G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. *Carcinogenesis* 2013, 34, 48–57. [CrossRef] [PubMed]
59. Hernan Perez de la Ossa, D.; Lorente, M.; Gil-Alegre, M.E.; Torres, S.; Garcia-Taboada, E.; Aberturas Mdel, R.; Molpeceres, J.; Velasco, G.; Torres-Suarez, A.I. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. *PLoS ONE* 2013, 8, e54795. [CrossRef] [PubMed]
60. Morelli, M.B.; Offidani, M.; Alesiani, F.; Discepoli, G.; Liberati, S.; Olivieri, A.; Santoni, M.; Santoni, G.; Leoni, P.; Nabissi, M. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. *Int. J. Cancer* 2014, 134, 2534–2546. [CrossRef]
61. Nabissi, M.; Morelli, M.B.; Offidani, M.; Amantini, C.; Gentili, S.; Soriani, A.; Cardinali, C.; Leoni, P.; Santoni, G. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. *Oncotarget* 2016, 7, 77543–77557. [CrossRef]
62. Good, P.D.; Greer, R.M.; Huggett, G.E.; Hardy, J.R. An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care. *J. Palliat. Med.* 2019. [CrossRef]
63. Brown, A.J. Novel cannabinoid receptors. *Br. J. Pharmacol.* 2007, 152, 567–575. [CrossRef]
64. Berdyshev, E.V. Cannabinoid receptors and the regulation of immune response. *Chem. Phys. Lipids* 2000, 108, 169–190. [CrossRef]
65. Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.; Denovan-Wright, E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br. J. Pharmacol.* 2015, 172, 4790–4805. [CrossRef] [PubMed]
66. Bénard, G.; Massa, F.; Puente, N.; Lourenço, J.; Belloccchio, L.; Soria-Gómez, E.; Matias, I.; Delamarre, A.; Metna-Laurent, M.; Cannich, A.; et al. Mitochondrial CB1 receptors regulate neuronal energy metabolism. *Nat. Neurosci.* 2012, 15, 558. Available online: https://www.nature.com/articles/nn.3053#supplementary-information (accessed on 12 February 2019). [CrossRef]
67. Nagarkatti, P.; Pandey, R.; Rieder, S.A.; Hegde, V.L.; Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. *Future Med. Chem.* 2009, 1, 1333–1349. [CrossRef] [PubMed]
68. Roche, M.; Finn, D.P. Brain CB(2) Receptors: Implications for Neuropsychiatric Disorders. *Pharmaceuticals* 2010, 3, 2517–2553. [CrossRef]
69. Galve-Roperh, I.; Sanchez, C.; Cortes, M.L.; Gomez del Pulgar, T.; Izquierdo, M.; Guzman, M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat. Med.* 2000, 6, 313–319. [CrossRef]
70. Sanchez, C.; de Ceballos, M.L.; Gomez del Pulgar, T.; Rueda, D.; Corbacho, C.; Velasco, G.; Galve-Roperh, I.; Huffman, J.W.; Ramon y Cajal, S.; Guzman, M. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. *Cancer Res.* 2001, 61, 5784–5789. [CrossRef]
71. Rosenthaler, S.; Pohn, B.; Kolmanz, C.; Huu, C.N.; Krewenka, C.; Huber, A.; Kranner, B.; Rausch, W.D.; Moldzio, R. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. *Neurotoxicol. Teratol.* 2014, 46, 49–56. [CrossRef]
72. Pertwee, R.G.; Howlett, A.C.; Abood, M.E.; Alexander, S.P.; Di Marzo, V.; Elphick, M.R.; Greasley, P.J.; Hansen, H.S.; Kunos, G.; Mackie, K.; et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). *Pharmacol. Rev.* 2010, 62, 588–631. [CrossRef]
73. Muller, C.; Morales, P.; Reggio, P.H. Cannabinoid Ligands Targeting TRP Channels. Front. Mol. Neurosci. 2018, 11, 487. [CrossRef]

74. Im, J.H.; Kang, K.W.; Kim, S.Y.; Kim, Y.G.; An, Y.J.; Park, S.; Jeong, B.H.; Choi, S.Y.; Lee, J.S.; Kang, K.W. GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. J. Exp. Clin. Cancer Res. 2018, 37, 295. [CrossRef]

75. Amantini, C.; Mosca, M.; Nabissi, M.; Lucciarini, R.; Caprodossi, S.; Arcella, A.; Giangaspero, F.; Santoni, G. Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J. Neurochem. 2007, 102, 977–990. [CrossRef] [PubMed]

76. Bode, A.M.; Cho, Y.Y.; Zheng, D.; Zhu, F.; Ericson, M.E.; Ma, W.Y.; Yao, K.; Dong, Z. Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res. 2009, 69, 905–913. [CrossRef] [PubMed]

77. Nabissi, M.; Morelli, M.B.; Amantini, C.; Farfariello, V.; Ricci-Vitiani, L.; Caprodossi, S.; Arcella, A.; Santoni, M.; Giangaspero, F.; De Maria, R.; et al. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis 2010, 31, 794–803. [CrossRef] [PubMed]

78. Lauckner, J.E.; Jensen, J.B.; Chen, H.Y.; Lu, H.C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA 2008, 105, 2699–2704. [CrossRef]

79. Liu, B.; Song, S.; Ruz-Maldonado, I.; Pingitore, A.; Huang, G.C.; Baker, D.; Jones, P.M.; Persaud, S.J. GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans. Diabetes Obes. Metab. 2016, 18, 1263–1273. [CrossRef]

80. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152, 1092–1101. [CrossRef]

81. Henstridge, C.M.; Balenga, N.A.; Ford, L.A.; Ross, R.A.; Waldhoer, M.; Irving, A.J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation.FASEB J. 2009, 23, 183–193. [CrossRef]

82. Falasca, M.; Corda, D. Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur. J. Biochem. 1994, 221, 383–389. [CrossRef]

83. Falasca, M.; Iurisci, C.; Carvelli, A.; Sacchetti, A.; Corda, D. Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts: a possible mechanism of autocrine control of cell proliferation. Oncogene 1998, 16, 2357–2365. [CrossRef]

84. Falasca, M.; Ferro, R. Role of the lysophosphatidylinositol/GPR55 axis in cancer. Adv. Biol. Regul. 2016, 60, 88–93. [CrossRef]

85. Pineiro, R.; Maffucci, T.; Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncology 2011, 30, 142–152. [CrossRef]

86. Hofmann, N.A.; Yang, J.; Trauger, S.A.; Nakayama, H.; Huang, L.; Strunk, D.; Moses, M.A.; Klagsbrun, M.; Bischoff, J.; Graier, W.F. The GPR55 agonist, L-alpha-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis. Br. J. Pharmacol. 2015, 172, 4107–4118. [CrossRef] [PubMed]

87. Ford, L.A.; Roelofs, A.J.; Anavi-Goffer, S.; Mowat, L.; Simpson, D.G.; Irving, A.J.; Rogers, M.J.; Rajnicek, A.M.; Ross, R.A. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br. J. Pharmacol. 2010, 160, 762–771. [CrossRef] [PubMed]

88. Kargl, J.; Andersen, L.; Hasenohrl, C.; Feuersinger, D.; Stancic, A.; Fauland, A.; Magnes, C.; El-Heliebi, A.; Lax, S.; Uranietsch, S.; et al. GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br. J. Pharmacol. 2016, 173, 142–154. [CrossRef] [PubMed]

89. Andrades, C.; Blasco-Benito, S.; Castillo-Lluva, S.; Dillenburg-Pilla, P.; Diez-Alarcia, R.; Juanes-Garcia, A.; Garcia-Taboada, E.; Hernando-Llorente, R.; Soriano, J.; Hamann, S.; et al. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget 2016, 7, 47565–47575. [CrossRef]

90. Yuan, Z.Y.; Dai, T.; Wang, S.S.; Peng, R.J.; Li, X.H.; Qin, T.; Song, L.B.; Wang, X. Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis. Onco Targets Ther. 2014, 7, 1733–1742. [CrossRef]

91. Ferro, R.; Adamska, A.; Lattanzio, R.; Mavrommati, I.; Edling, C.E.; Ariffin, S.A.; Fyffe, C.A.; Sala, G.; Sacchetti, L.; Chiorino, G.; et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 2018. [CrossRef]
92. Zheng, C.; Jiao, X.; Jiang, Y.; Sun, S. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J. Int. Med. Res. 2013, 41, 300–306. [CrossRef]
93. Laun, A.S.; Song, Z.H. GPR3 and GPR6, novel molecular targets for cannabidiol. Biochem. Biophys. Res. Commun. 2017, 490, 17–21. [CrossRef]
94. Laun, A.S.; Shrader, S.H.; Brown, K.J.; Song, Z.H. GPR3, GPR6, and GPR12 as novel molecular targets: Their biological functions and interaction with cannabidiol. Acta Pharmacol. Sin. 2019, 40, 300–308. [CrossRef]
95. Apostolou, P.; Toloudi, M.; Papasotiriou, I. Identification of genes involved in breast cancer and breast cancer stem cells. Breast Cancer 2015, 7, 183–191. [CrossRef]
96. Breivogel, C.S.; McPartland, J.M.; Parekh, B. Investigation of non-CB1, non-CB2 WIN55212-2-sensitive G-protein-coupled receptors in the brains of mammals, birds, and amphibians. J. Recept. Signal Transduct. Res. 2018, 38, 316–326. [CrossRef] [PubMed]
97. Massi, P.; Vaccani, A.; Cerutti, S.; Colombo, A.; Abbracchio, M.P.; Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther. 2004, 308, 838–845. [CrossRef]
98. Punzo, F.; Manzo, I.; Tortora, C.; Pota, E.; Angelo, V.; Di Paola, A.; Verace, F.; Casale, F.; Rossi, F. Effects of CB2 and TRPV1 receptors’ stimulation in pediatric acute T-lymphoblastic leukemia. Oncotarget 2018, 9, 21244–21258. [CrossRef] [PubMed]
99. Casanova, M.L.; Blazquez, C.; Martinez-Palacio, J.; Villanueva, C.; Fernandez-Acenero, M.J.; Huffman, J.W.; Jorcano, J.L.; Guzman, M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Investig. 2003, 111, 43–50. [CrossRef] [PubMed]
100. Blazquez, C.; Gonzalez-Feria, L.; Alvarez, L.; Haro, A.; Casanova, M.L.; Guzman, M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004, 64, 5617–5623. [CrossRef]
101. Elbaz, M.; Ahirwar, D.; Ravi, J.; Nagoski, M.; Ghassabian, H. Novel role of cannabinoid receptor 2 in inhibiting EGFR/EGFR and IGF-I/IGF-IR pathways in breast cancer. Oncotarget 2017, 8, 29668–29678. [CrossRef]
102. Dun, M.D.; Chalkley, R.J.; Faulkner, S.; Keene, S.; Avery-Kiejda, K.A.; Scott, R.J.; Falkenby, L.G.; Cairns, M.J.; Blazquez, C.; Gonzalez-Feria, L.; Alvarez, L.; Haro, A.; Casanova, M.L.; Guzman, M. Opposite changes in cannabinoid CB2 receptor expression in endothelial cells of glioblastoma in humans. Neurochem. Int. 2013, 64, 29668–29678. [CrossRef]
103. Degryse, S.; de Bock, C.E.; Demeyer, S.; Govaerts, I.; cone, S.; Jacobs, K.; Binos, S.; Skerrett-Byrne, D.A.; Murray, H.C.; et al. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 2018, 32, 788–800. [CrossRef]
104. R Mokoena, D.; P George, B.; Abrahamse, H. Enhancing Breast Cancer Treatment Using a Combination of Cannabidiol and Gold Nanoparticles for Photodynamic Therapy. Int. J. Mol. Sci. 2019, 20, 4771. [CrossRef]
105. Ellert-Miklaszewska, A.; Ciechomska, I.; Kaminska, B. Cannabinoid signaling in glioma cells. Adv. Exp. Med. Biol. 2013, 986, 209–220. [CrossRef]
106. De Jesus, M.L.; Hostalot, C.; Caribi, J.M.; Salles, J.; Meana, J.J.; Callado, L.F. Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. Neurochem. Int. 2010, 56, 829–833. [CrossRef]
107. Schley, M.; Stander, S.; Kern, J.; Vajkoczy, P.; Schupfer, G.; Dusch, M.; Schmelz, M.; Konrad, C. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res. Bull. 2009, 79, 333–337. [CrossRef]
108. Wu, X.; Han, L.; Zhang, X.; Li, L.; Jiang, C.; Qiu, Y.; Huang, R.; Xie, B.; Lin, Z.; Ren, J.; et al. Alteration of endocannabinoid system in human gliomas. J. Neurochem. 2012, 120, 842–849. [CrossRef]
109. Ciaglia, E.; Torelli, G.; Pisanti, S.; Picardi, P.; D’Alessandro, A.; Laezza, C.; Malfitano, A.M.; Fiore, D.; Pagano Zottola, A.C.; Proto, M.C.; et al. Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients’ cells. Oncotarget 2015, 6, 15464–15481. [CrossRef]
110. Dumitru, C.A.; Sandalcioglu, I.E.; Karsak, M. Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs. Front. Mol. Neurosci. 2018, 11. [CrossRef]
111. Duchatel, R.J.; Jackson, E.R.; Alvaro, F.; Nixon, B.; Hondermarck, H.; Dun, M.D. Signal Transduction in Diffuse Intrinsic Pontine Glioma. Proteomics 2019, e1800479. [CrossRef]
112. McAllister, S.D.; Sorocanu, L.; Desprez, P.Y. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. J. Neuroimmune Pharmacol. 2015, 10, 255–267. [CrossRef]
113. Herrera, B.; Carracedo, A.; Diez-Zaera, M.; Guzman, M.; Velasco, G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. *Exp. Cell Res.* 2006, 321, 1211–1213. [CrossRef] [PubMed]

114. Preet, A.; Qamri, Z.; Nasser, M.W.; Prasad, A.; Shilo, K.; Zou, X.; Groopman, J.E.; Ganju, R.K. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev. Res.* 2011, 4, 65–75. [CrossRef]

115. Caffarel, M.M.; Sarrio, D.; Palacios, J.; Guzman, M.; Sanchez, C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. *Cancer Res.* 2006, 66, 6615–6621. [CrossRef]

116. Herrera, B.; Carracedo, A.; Gironella, M.; Lorente, M.; Garcia, S.; Guzman, M.; Velasco, G.; et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J. Clin. Investig.* 2009, 119, 1359–1372. [CrossRef]

117. Hart, S.; Fischer, O.M.; Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. *Cancer Res.* 2004, 64, 1943–1950. [CrossRef] [PubMed]

118. Mimeault, M.; Pommery, N.; Wattez, N.; Bailly, C.; Henichart, J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. *Prostate* 2003, 56, 1–12. [CrossRef] [PubMed]

119. Carracedo, A.; Gironella, M.; Lorente, M.; Garcia, S.; Guzman, M.; Velasco, G.; Iovanna, J.L. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. *Cancer Res.* 2006, 66, 6748–6755. [CrossRef] [PubMed]

120. Herrera, B.; Carracedo, A.; Diez-Zaera, M.; Perez del Pulgar, T.; Guzman, M.; Velasco, G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. *Exp. Cell Res.* 2006, 312, 2121–2131. [CrossRef] [PubMed]

121. Salazar, M.; Carracedo, A.; Salanueva, I.J.; Hernandez-Tiedra, S.; Lorente, M.; Egia, A.; Vazquez, P.; Blazquez, C.; Torres, S.; Garcia, S.; et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *J. Clin. Investig.* 2009, 119, 1359–1372. [CrossRef]

122. Massi, P.; Solinas, M.; Cinquina, V.; Parolaro, D. Cannabidiol as potential anticancer drug. *Br. J. Clin. Pharmacol.* 2013, 75, 303–312. [CrossRef]

123. Shrivastava, A.; Kuzontkoski, P.M.; Groopman, J.E.; Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol. Cancer Ther.* 2011, 10, 1161–1172. [CrossRef]

124. Chen, Q.; Kang, J.; Fu, C. The independence of and associations among apoptosis, autophagy, and necrosis. *Signal Transduct. Target. Ther.* 2018, 3, 18. [CrossRef]

125. Jacobsson, S.O.; Wallin, T.; Fowler, C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. *J. Pharmacol. Exp. Ther.* 2001, 299, 951–959. [CrossRef]

126. Goncharov, I.; Weiner, L.; Vogel, Z. Delta9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. *Neuroscience* 2005, 134, 567–574. [CrossRef]

127. Massi, P.; Vaccani, A.; Bianchessi, S.; Costa, B.; Macchi, P.; Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. *Cell. Mol. Life Sci.* 2006, 63, 2057–2066. [CrossRef]

128. Sillar, J.R.; Germon, Z.P.; DeJuliius, G.N.; Dun, M.D. The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia. *Int. J. Mol. Sci.* 2019, 20, 6003. [CrossRef]

129. Chandra, L.C.; Kumar, V.; Torben, W.; Vande Stouwe, C.; Winsauer, P.; Amedee, A.; Molina, P.E.; Mohan, M. Chronic administration of Delta9-tetrahydrocannabinol induces intestinal anti-inflammatory microRNA expression during acute simian immunodeficiency virus infection of rhesus macaques. *J. Virol.* 2015, 89, 1168–1181. [CrossRef]

130. Olivas-Aguirre, M.; Torres-López, L.; Valle-Reyes, J.S.; Hernández-Cruz, A.; Pottosin, I.; Dobrovinskaya, O. Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia. *Cell Death Dis.* 2019, 10, 779. [CrossRef]

131. O’Sullivan, S.E.; Sun, Y.; Bennett, A.J.; Randall, M.D.; Kendall, D.A. Time-dependent vascular actions of cannabidiol in the rat aorta. *Eur. J. Pharmacol.* 2009, 612, 61–68. [CrossRef]
132. Kenyon, J.; Liu, W.; Dalgleish, A. Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. *Anticancer Res.* **2018**, *38*, 5831–5835. [CrossRef]

133. Likar, R.; Koestenberger, M.; Stultschnig, M.; Nahler, G. Concomitant Treatment of Malignant Brain Tumours with CBD—A Case Series and Review of the Literature. *Anticancer Res.* **2019**, *39*, 5797–5801. [CrossRef]

134. Pellati, F.; Borgonetti, V.; Brighenti, V.; Biagi, M.; Benvenuti, S.; Corsi, L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. *Biomed. Res. Int.* **2018**, 2018, 1691428. [CrossRef]

135. Herring, A.C.; Koh, W.S.; Kaminski, N.E. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabionol, a minimally CNS-active cannabinoid. *Biochem. Pharmacol.* **1998**, *55*, 1013–1023. [CrossRef]

136. Elbaz, M.; Nasser, M.W.; Ravi, J.; Wani, N.A.; Ahirwar, D.K.; Zhao, H.; Oghumu, S.; Satoskar, A.R.; Shilo, K.; Carson, W.E.; et al. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer. *Mol. Oncol.* **2015**, *9*, 906–919. [CrossRef]

137. Izzo, A.A.; Camilleri, M. Cannabinoids in intestinal inflammation and cancer. *Pharmacol. Res.* **2009**, *60*, 117–125. [CrossRef]

138. Staudt, D.; Murray, H.C.; McLachlan, T.; Alvaro, F.; Enjeti, A.K.; Verrills, N.M.; Dun, M.D. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. *Int. J. Mol. Sci.* **2018**, *19*, 3198. [CrossRef]

139. Likar, R.; Kostenberger, M.; Nahler, G. Cannabidiol in cancer treatment. *Schmerz* **2020**. [CrossRef]

140. Faulkner, S.; Dun, M.D.; Hondermarck, H. Proteogenomics: Emergence and promise. *Cell. Mol. Life Sci.* **2015**, *72*, 953–957. [CrossRef]

141. Murray, H.C.; Dun, M.D.; Verrills, N.M. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. *Expert Opin. Drug Discov.* **2017**, *12*, 431–447. [CrossRef]